Verona Emerges Victorious From Second COPD Trial
Ensifentrine Will Head To FDA In First Half Of 2023
After once again showing significant improvements in lung function and a 36% reduction in rate of exacerbations over 24 weeks, Verona is confident that its dual PDE3/4 inhibitor will change the treatment paradigm for COPD.
You may also be interested in...
The UK firm's ensifentrine has exceeded analyst expectations by cutting the rate of moderate to severe COPD exacerbations by 42% over 24 weeks.
The UK biotech will have no problems funding a Phase III program for its nebulized first-in-class COPD therapy ensifentrine as investors old and new flocked to buy into the stock.
The Swedish biotech is stepping up its business development plans ahead of a mid-stage readout in the summer for ACD440, its TRPV1 antagonist for neuropathic pain.